Introduction
LGC’s equine blood drug screening service is designed to test for the possible presence of a wide range of drugs. Screening is the first of a two-stage doping control programme and is offered as part of a prepurchase examination, for a change of insurance company or to facilitate horse exportation only. Samples will be accepted on the understanding that detection of a prohibited substance will be confirmed by a second, rigorous confirmatory analysis (separate service details and prices available on request).

Technical Description of Service
- The sample testing process is performed in line with LGC’s fixed and flexible scopes of accreditation in accordance with ISO/IEC 17025:2017 ‘General requirements for the competence of testing and calibration laboratories’ [www.UKAS.org](http://www.UKAS.org) All methods used are accredited to this standard unless otherwise stated and a list of the validated methods is maintained using controlled document SPT ID 4022: ISO 17025 Validated Methods.
- Technical information such as Uncertainty of Measurement and reporting limits for specific SOPs are available on request.
- Substances with screening limits will be analysed in accordance with the AORC Guidelines for Controlling Screening Limits ([http://www.aorc-online.org/documents/guidelines-for-controlling-screening-limits/](http://www.aorc-online.org/documents/guidelines-for-controlling-screening-limits/)) as required within ILAC-G7:04/2021 [https://www.aorc-online.org/resources/ilac-g7-related-documents/](https://www.aorc-online.org/resources/ilac-g7-related-documents/) Technical information about the approach and any reporting margins are available on request.
- All sample information is recorded, tracked, and archived using LIMS (laboratory information management system. Integrity checks are applied to each sample, which is then stored securely in a controlled environment.
- A screening protocol consisting of a number of different tests and analytical techniques is applied to each sample. Routine techniques are mass spectrometry (including accurate mass analysis), gas chromatography and liquid chromatography.
- The tests detect a wide range of drugs and metabolites including, but not restricted to, the following classes: Analgesics, antihistamines, beta-blockers, bronchodilators, diuretics, local anaesthetics, non-steroidal anti-inflammatory drugs (NSAIDs), sedatives, stimulants, synthetic corticosteroids and tranquillisers.
- The specification (range of drugs and sensitivities) of individual tests routinely applied meets the requirements of the International Federation of Horseracing Authorities (IFHA).
- Prepurchase blood samples will be analysed using the following screens and LGC methods include General Screen (acidic/neutral) for Plasma (SOP4110), Corticosteroids in Urine and Plasma (SOP4107) and Basic Drugs in Plasma (SOP4093).
- The stability of individual analytes in matrix prior to testing of the sample is not routinely assessed and samples are analysed in the condition that they are received.

Submitting a sample for immediate analysis
- Complete all fields of the paperwork and tick to request immediate analysis.
- Ensure the sample is securely packaged and that paperwork is included with the package.
- Receipts, results, and invoices will be sent directly to your practice by email.
  - A receipt acknowledges the request for analysis. Screening analysis turnaround time is 7 working days.

Requesting analysis of a sample held in storage
- From the practice email account, note your request, include the code (e.g., 1234ABC) and horse name, and send to equine.submissions@lgcgroup.com
- Receipts, results, and invoices will be sent directly to your practice by email.
  - The A receipt acknowledges the request for analysis. Screening analysis turnaround is 7 working days.
Sample Disposal
Samples under a prepurchase agreement
- Negative samples will be retained for the remainder of the storage period.
- Non-negative samples are retained until confirmatory analysis instructions are received. If no confirmatory analysis is performed the sample will be retained for the remainder of the storage period.

Samples not under a prepurchase agreement
- Negative samples will be disposed of once results have been reported.
- Non-negative samples are retained until confirmatory analysis instructions are received. If no confirmatory analysis is performed the sample will be disposed of.

All samples reported to contain prohibited substances will be securely stored for six months. These samples will then be disposed unless further instruction is received from the customer. A further charge will be made for prolonged sample storage.

Fee Schedule

<table>
<thead>
<tr>
<th>Service</th>
<th>Detail of Service</th>
<th>Price ex VAT GBP</th>
<th>Price ex VAT EUR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepurchase blood Screen</td>
<td>NSAIDs, Sedatives, &amp; Synthetic Corticosteroids</td>
<td>308</td>
<td>400</td>
</tr>
<tr>
<td>Fast-Track NSAIDs</td>
<td>NSAIDs screening only – 4 working day turnaround time</td>
<td>308</td>
<td>400</td>
</tr>
<tr>
<td>Export Screen</td>
<td>Including NSAIDs, Sedatives, &amp; Synthetic Corticosteroids</td>
<td>308</td>
<td>400</td>
</tr>
<tr>
<td>Admin fee</td>
<td>Cancellation of testing</td>
<td>117</td>
<td>140</td>
</tr>
<tr>
<td>Extended Storage</td>
<td>Additional 6 months storage</td>
<td>88</td>
<td>108</td>
</tr>
<tr>
<td>Sample Return</td>
<td>Return of samples unsuitable for storage/analysis</td>
<td>28</td>
<td>32</td>
</tr>
</tbody>
</table>

Prices Valid from 01/Apr/2024 until 31/Mar/2025

General Terms and Conditions
Minimum blood volume required for screening - 6mls. Please note pre-spun plasma will not be accepted. Vacutainers MUST be labelled. All work will be undertaken in accordance with the current LGC T&Cs.

Customer Complaints
Should the customer wish to raise a complaint then this should be sent to LGC via email to equine.submissions@lgcgroup.com. Upon the receipt of the complaint, LGC will confirm whether the complaint relates to L activities that LGC is responsible for and, if so, deal with it. The complaint will be recorded and reviewed using the laboratory eQMS system and FORM 10807. LGC will inform the customer via email of the outcome of any complaint.

Please sign and return via email, this is required before any analysis can proceed.
Provision of Prepurchase analysis
THIS AGREEMENT IS COMPLETELY CONFIDENTIAL BETWEEN THE DOCUMENTED PARTIES AS PER SECTION 12 OF LGC’S STANDARD T&CS.

Signed for and on behalf of Customer:

**SIGNATURE** ________________________________ **DATE** __________

**NAME** ___________________________________________

**POSITION** ________________________________________